Teriparatide as an adjuvant therapy in the management of advanced-stage medication-related osteonecrosis of the jaw Journal Article
| Authors: | Singh, A.; Chung, K.; Huryn, J. M.; Estilo, C. L.; Farooki, A.; Yom, S. K. |
| Article Title: | Teriparatide as an adjuvant therapy in the management of advanced-stage medication-related osteonecrosis of the jaw |
| Abstract: | Teriparatide, recombinant human parathyroid hormone, is a US Food and Drug Administration (FDA)-approved drug used for the treatment of osteoporosis in men and postmenopausal women. Recent studies have shown that it may promote bone healing in medication-related osteonecrosis of the jaw (MRONJ). We describe a case of successful management of advanced-stage MRONJ with teriparatide therapy that was initially prescribed for osteoporosis. This case demonstrates that in patients with progressive MRONJ with significant pain and frequent flares of acute infection, teriparatide may be a viable adjunct in treating MRONJ, as well as helping alleviate symptoms and improve quality of life. (Oral Surg Oral Med Oral Pathol Oral Radiol YEAR;VOL:page range) © 2025 |
| Journal Title: | Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology |
| ISSN: | 2212-4403 |
| Publisher: | Elsevier B.V. |
| Publication status: | Online ahead of print |
| Date Published: | 2025-04-10 |
| Online Publication Date: | 2025-04-10 |
| Language: | English |
| DOI: | 10.1016/j.oooo.2025.04.001 |
| PROVIDER: | scopus |
| PUBMED: | 40399210 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF. Corresponding MSK author is SaeHee K. Yom -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work